Management Team

Dr. HH Ting

Dr. Ting is a scientist, entrepreneur and angel investor. He has extensive experience in the Chinese healthcare sector, in particular in nuclear medicine. Most recently, he served as CEO and co-founder of Oxford Vacmedix and Biovue Ltd. He was also the founder of Genemedix Plc., a Chinese biotechnology company. Earlier in his career, he was the China General Manager of Amersham International Plc. and worked as a consultant for Westinghouse Electric, J&J and GE Healthcare. Dr. Ting received his academic training and DPhil degree in biochemistry from the University of Oxford.




Mr. Henry HH Ho

Mr. Ho has over 30 years of operational, financial and investment experience in industries that include healthcare, technology, manufacturing and media. Prior to joining NanoMab, he served as the GM of Ningbo JACO Pharmaceutical Co., Ltd. and was responsible for the expansion of its nuclear medicine product line. He also served as director of Tasly Pharmaceutical Group and co-founded Oxford VacMedix. He has held various senior positions at different financial institutions, including Greater China head at Baring Asset Management Asia, Founder of Atlantis Investment Management Asia and China research head at Morgan Stanley, Merrill Lynch and UBS. He also has strong financial operations and fundraising experience. Mr. Ho holds a master’s degree in accounting and finance from the Lancaster University, UK and he is a qualified accountant of HKICPA.



Mr. James MP Poon

Mr. Poon has over 25 years of experience in the global investment banking industry with his last position as CEO of Yuanta Securities in Hong Kong. He has held various senior positions at other financial institutions including Cazenove, Smith New Court, Kleinwort Benson, UBS and CICC. During his time at the above organizations, James was deeply involved, in the capacity as a senior banker, in many landmark equity fundraisings. Since leaving the industry Mr. Poon has actively worked in the field of PE and VC investments. He has invested in over 30 deals over the last 7 years. He has a master’s degree in International Accounting & Finance from the London School of Economics and Political Science.




Mr. Shankar Seetharaman
Head of Regulatory & Quality

Mr. Seetharaman has over 20 years international experience at major pharmaceutical companies covering Quality Control, QA management, Quality and Regulatory Affairs. He specializes in quality systems, auditing, validation and contractor management, especially for companies in the early phases of development. He has helped to qualify numerous PET centers and their FDG production facilities across Europe and served as visiting lecturer at King’s College London. Mr. Seetharaman is a Chartered Quality Professional, Member of the Chartered Quality Institute and Fellow of the Royal Society of Biology. He is also qualified as a Market Research Quality Analyst.




Mr. WH Huang
China General Manager

Mr. Huang has over 20 years of experience in research, development and commercialization in the Chinese biotechnology sector. Prior to joining NanoMab, he was an associate professor at The Institute of Translational Medicine of Shanghai General Hospital. He also served as the SVP of Cell Signaling Company and R&D director of Shanghai State Biotechnology Co., Ltd. Mr. Huang holds a master’s degree in bioengineering from Fudan University and an MBA from Richmond Business Administration College.





Dr. Nicholas CL Wong
Project Director

Nicholas has broad experience in the development of innovative cancer treatments. Prior to joining NanoMab, he held the position of project manager in Jiangsu Laitai Medical Biotech Ltd, responsible for the early development of a liver cancer specific peptide pharmaceutical. He also served as application scientist at Roche Diagnostic where he was in charge of implementing cancer molecular diagnostics in Hong Kong. Nicholas is a founder of Novus Life Sciences Ltd, a Hong Kong Science and Technology Park biotechnology incubator company focusing on the development of novel bone cement formulations. Nicholas received his academic training and PhD in cancer biology from the University of Hong Kong.




Dr. Gitasha Chand
Clinical Research Director

Gitasha has extensive experience in the clinical development of radiopharmaceuticals. Immediately prior to joining NanoMab, she was a clinical research associate at Jiangsu Laitai Medical Biotech Ltd, in charge of the China-wide clinical development of Re-188 HEDP, a radiopharmaceutical for the palliative treatment of patients with metastatic bone disease. Earlier in her career, she was a resident trainee at Shanghai East Hospital and Shanghai Bao Shan CDC where she performed extensive research on infectious diseases. Gitasha holds an MBBS from Tongji University Medical School, Shanghai and she is specialized in emergency and disaster medicine.




Dr. Levente Meszaros
Senior Project Manager

Levente has over 10 years of experience in the development of radiopharmaceuticals. Earlier in his career he worked as a research associate and radiation protection supervisor at King’s College London, where his research focused on the development of radiopharmaceuticals targeting osteolytic bone disease and novel tracers for ex vivo cell radiolabeling. Upon leaving King’s College London he worked at BioProbe Ltd as project leader and at Theragnostics Ltd as quality control scientist. Levente holds master’s degrees in chemistry, clinical chemistry and radiopharmaceutics from the University of Szeged, Hungary and King’s College London and a PhD in imaging sciences and radiation biology from King’s College London.